Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118538) titled 'A single-arm, prospective, phase II study of Glofitamab in combination with Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin,and Prednisone (Pola-R-CHP) to optimize primary therapy in patients with high-risk Diffuse Large B-Cell Lymphoma assessed by interim FDG PET and ctDNA' on Feb. 6.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Peking Union Medical College Hospital
Condition:
Diffuse Large B-Cell Lymphoma
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-03-01
Target Sample Size: Experimental group:42;
Countries of Recruitmen...